List of works - Jacob D Soumerai

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy

scientific article published on 01 March 2009

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

scientific article published on 23 January 2008

Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever

scientific article published on 01 February 2019

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

scientific article

Diagnosis and management of Castleman disease.

scientific article

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

scientific article

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials

scientific article published on 08 November 2018

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

scientific article published on 06 February 2009

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.

scientific article published in January 2007

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs

scientific article published on 8 December 2008

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

scientific article

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

scientific article

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

scientific article

Novel agents in the treatment of Waldenström's macroglobulinemia.

scientific article published on August 2007

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia

scientific article published on 10 May 2019

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

scientific article

Thalidomide and rituximab in Waldenstrom macroglobulinemia

scientific article

The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

scientific article published on 3 June 2008

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

scientific article

The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.

scientific article published on 15 July 2016

Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

scientific article published on 15 July 2020

Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.

scientific article

List of works by Jacob D Soumerai

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

Diagnosis and management of Castleman disease.

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Novel agents in the treatment of Waldenström's macroglobulinemia.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

Thalidomide and rituximab in Waldenstrom macroglobulinemia

The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.

Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.